Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03123783
Title CD40 Agonistic Antibody APX005M in Combination With Nivolumab
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Apexigen, Inc.
Indications

lung non-small cell carcinoma

Therapies

APX005M + Nivolumab

Age Groups: senior | adult
Covered Countries USA | ESP


No variant requirements are available.